Tracers / [177Lu]Lu-HTK03149
[177Lu]Lu-HTK03149
Also written as [Lu-177]Lu-HTK03149
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- PSMA-targeting Lys-urea-Glu-based small molecule radioligand (Aad analog)
- Target / mechanism
- PSMA (prostate-specific membrane antigen) binding via Lys-urea-Glu pharmacophore PMID 36168623
- Clinical application
- Radioligand therapy of PSMA-expressing prostate cancer, promising for clinical translation PMID 36168623
- Theranostic pair
- <a href="/tracers/ga68-htk03149/">ga68-htk03149</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | HPLC | — | — | HTK03149 | 36168623 2022 Theranostics |
Need this precursor?We can point you to suppliers for [177Lu]Lu-HTK03149, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36168623. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.